Alpha-immunotherapy
Astatine against cancer
Developing a new generation of radiopharmaceuticals using astatine-211, an alpha-emitting radionuclide, to selectively destroy residual cancer cells.
Offering patients a longer life of better quality
Proprietary technology
Innovative radiolabeling with astatine-211 for targeted destruction of tumor cells.
Therapeutic precision
Alpha particles with a very short range, sparing surrounding healthy tissues.
Operational excellence
Experienced team from the Nantes nuclear medicine cluster.
We develop innovative radiopharmaceutical products to destroy the last remaining cancer cells of residual disease left after conventional treatments. Our alpha-immunotherapy addresses clinical indications with genuine unmet therapeutic needs.
A highly promising disruptive innovation
Innovative targeted alpha radiotherapy programs to treat resistant cancers.
The technology developed by Atonco is a highly promising disruptive innovation in the eradication of microscopic residual disease or isolated or clustered residual tumor cells that are rapidly accessible to a radiopharmaceutical labeled with astatine-211.
ATO-101™
Girentuximab radiolabeled with astatine-211 for non-muscle-invasive bladder tumors (NMIBT) resistant to BCG.
Clinical dose production
Development and validation of the radiopharmaceutical production process in compliance with regulatory quality requirements.
Research & Innovation
Exploration of new indications suited to the characteristics of astatine-211.
Bladder cancer: An unmet medical need
A major therapeutic challenge requiring innovative approaches
Bladder cancer is one of the most widespread malignant tumors in the world, with approximately 614,000 new cases diagnosed each year. It ranks 9th among the most common cancers and 6th among men.
Despite current treatments, particularly BCG immunotherapy, approximately 40% of patients experience treatment failure, highlighting the urgent need for innovative therapeutic approaches such as the alpha-immunotherapy developed by Atonco.
Source: gco.iarc.who.int